TR200003787A2 - Kararlı yavaş salımlı oral dozaj bileşimi. - Google Patents

Kararlı yavaş salımlı oral dozaj bileşimi.

Info

Publication number
TR200003787A2
TR200003787A2 TR2000/03787A TR200003787A TR200003787A2 TR 200003787 A2 TR200003787 A2 TR 200003787A2 TR 2000/03787 A TR2000/03787 A TR 2000/03787A TR 200003787 A TR200003787 A TR 200003787A TR 200003787 A2 TR200003787 A2 TR 200003787A2
Authority
TR
Turkey
Prior art keywords
oral dosage
allergic
dosage composition
allergic rhinitis
symptoms
Prior art date
Application number
TR2000/03787A
Other languages
English (en)
Turkish (tr)
Other versions
TR200003787A3 (tr
Inventor
H. Kou Jim
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22629437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200003787(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of TR200003787A3 publication Critical patent/TR200003787A3/tr
Publication of TR200003787A2 publication Critical patent/TR200003787A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Toys (AREA)
  • Cosmetics (AREA)
TR2000/03787A 1999-12-20 2000-12-20 Kararlı yavaş salımlı oral dozaj bileşimi. TR200003787A2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17283699P 1999-12-20 1999-12-20

Publications (2)

Publication Number Publication Date
TR200003787A3 TR200003787A3 (tr) 2001-07-23
TR200003787A2 true TR200003787A2 (tr) 2001-07-23

Family

ID=22629437

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03787A TR200003787A2 (tr) 1999-12-20 2000-12-20 Kararlı yavaş salımlı oral dozaj bileşimi.

Country Status (37)

Country Link
US (2) US6979463B2 (enExample)
EP (2) EP1112738B1 (enExample)
JP (3) JP5042403B2 (enExample)
KR (2) KR100936572B1 (enExample)
CN (3) CN1679569A (enExample)
AR (1) AR027033A1 (enExample)
AT (1) ATE463240T1 (enExample)
AU (4) AU2277101A (enExample)
BR (1) BR0006403A (enExample)
CA (1) CA2329217C (enExample)
CO (1) CO5251435A1 (enExample)
CY (1) CY1110693T1 (enExample)
CZ (1) CZ302860B6 (enExample)
DE (1) DE60044117D1 (enExample)
DK (1) DK1112738T3 (enExample)
EC (1) ECSP003836A (enExample)
EG (1) EG23759A (enExample)
ES (1) ES2341751T3 (enExample)
HU (1) HUP0004988A3 (enExample)
ID (1) ID28675A (enExample)
IL (1) IL140450A (enExample)
MX (1) MXPA00013037A (enExample)
MY (1) MY130773A (enExample)
NO (1) NO331645B1 (enExample)
NZ (1) NZ509028A (enExample)
PE (1) PE20010982A1 (enExample)
PL (1) PL211573B1 (enExample)
PT (1) PT1112738E (enExample)
RU (2) RU2303440C2 (enExample)
SA (2) SA06270069B1 (enExample)
SG (1) SG109438A1 (enExample)
SI (1) SI1112738T1 (enExample)
SK (1) SK287684B6 (enExample)
TR (1) TR200003787A2 (enExample)
TW (1) TWI225414B (enExample)
WO (1) WO2001045668A2 (enExample)
ZA (1) ZA200007715B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2277101A (en) 1999-12-20 2001-07-03 Schering Corporation Stable extended release oral dosage composition
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
WO2003000264A1 (en) * 2001-06-20 2003-01-03 Schering Corporation Antihistamines for the treatment of nasal congestion and nasal obstruction
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
AU2003211146B2 (en) * 2002-02-21 2007-07-19 Valeant International (Barbados) Srl Controlled release dosage forms
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
WO2004080461A2 (en) * 2003-03-12 2004-09-23 TEVA Gyógyszergyár Részvénytársaság Stable pharmaceutical compositions of desloratadine
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
WO2005053599A1 (ja) * 2003-12-01 2005-06-16 Takeda Pharmaceutical Company Limited 固形製剤の印刷前処理方法及び印刷前処理方法が施された固形製剤
MX2007004976A (es) * 2004-10-25 2007-06-14 Schering Corp Antagonistas de receptor m1 y/o m3 en combinacion con otros compuestos activos para tratar trastornos respiratorios.
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20070014855A1 (en) * 2005-07-12 2007-01-18 Rahul Gawande S Stable desloratadine compositions
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US8068991B2 (en) 2005-11-30 2011-11-29 The Invention Science Fund I, Llc Systems and methods for transmitting pathogen related information and responding
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
FR2894143B1 (fr) * 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
CN101472561A (zh) * 2006-06-01 2009-07-01 先灵公司 去氧肾上腺素脉冲释放制剂和药物组合物
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
MX2008015358A (es) * 2006-06-01 2009-03-06 Schering Corp Composiciones farmaceuticas para liberacion sostenida de fenilefrina.
CA2653953C (en) * 2006-06-01 2015-12-08 Schering-Plough Healthcare Products, Inc. Phenylephrine pharmaceutical formulations and compositions for colonic absorption
CA2658170A1 (en) * 2006-07-11 2008-01-17 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
CA2697959A1 (en) * 2007-06-01 2008-12-11 Schering-Plough Healthcare Products, Inc. Pharmaceutical composition comprising a substrate and a coating containing an active ingredient and polyvinylalcohol
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
WO2010143202A1 (en) * 2009-06-09 2010-12-16 Sun Pharmaceutical Industries Ltd. Pharmaceutical composition
TR201009396A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Desloratadin granüller
DE102016107760B4 (de) * 2016-04-26 2018-09-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Essbare Funktionsschichten und Überzüge auf Hybridpolymerbasis für Pharmazie und Lebensmittel
US10463656B2 (en) 2017-01-05 2019-11-05 Iowa State University Research Foundation, Inc. Methods and compositions for prevention of feedlot bovine respiratory disease
EP4188339A1 (en) 2020-07-30 2023-06-07 Faes Farma, S.A. Decongestant drug delivery system
WO2026104388A1 (en) 2024-11-12 2026-05-21 Faes Farma, S.A. Decongestant controlled release drug delivery system

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US100000A (en) 1870-02-22 Improved sun-bonnet for horses
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3940485A (en) 1973-12-12 1976-02-24 Levinson Harold N Treatment and pre-treatment of dysmetric dyslexia by improving sequential scanning and ocular fixation abilities and therapeutic compounds
US4008796A (en) 1974-03-26 1977-02-22 General Concrete Of Canada Limited Control method for feeding items on a conveyor
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
WO1985003707A1 (en) 1984-02-15 1985-08-29 Schering Corporation 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO AD5,6 BDCYCLOHEPTA AD1,2-b BDPYRIDINE AND ITS SALTS, PROCESSES FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4783465A (en) 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
SE8404467D0 (sv) 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
US4731447A (en) 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4804666A (en) 1985-08-14 1989-02-14 Schering Corporation Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines
JPS6396126A (ja) 1986-10-13 1988-04-27 Taisho Pharmaceut Co Ltd 安定化組成物
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US4777170A (en) 1987-02-03 1988-10-11 Heinrich William A Method to prevent and treat the signs and symptoms of motion sickness
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
US4863931A (en) 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
US5019591A (en) 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
US4990535A (en) 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
NZ238629A (en) 1990-06-22 1993-09-27 Schering Corp Bis-benzo- or benzopyrido-cyclohepta (where z is c, o, s or n) piperidine, piperidylidene or piperazine compounds, medicaments and methods of preparation
DE69120430D1 (de) 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
PT100502A (pt) 1991-05-20 1993-08-31 Alza Corp Composicoes farmaceuticas para aumentar a capacidade de permeacao na pele utilizando monolinoleato de glicerol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
ES2042421B1 (es) 1992-05-22 1994-08-01 Uriach & Cia Sa J Procedimiento para la obtencion de la 8-cloro-11-*1-*(5-metil-3-piridil)metil*-4-piperidiliden*-6,11-dihidro-5h-benzo*5,6*ciclohepta*1,2-b*piridina.
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
JP2646972B2 (ja) 1993-11-01 1997-08-27 日本電気株式会社 多ビットメモリ
DE4442999A1 (de) 1994-12-02 1996-06-05 Hexal Pharma Gmbh Pharmazeutische Zusammensetzung mit einem aktiven Loratidin-Metaboliten
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US5807579A (en) * 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
JP3220373B2 (ja) * 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
BR9712705A (pt) * 1996-10-31 1999-10-26 Schering Corp Composição para o tratamento da asma, contendo loratadina e um descongestionante
TW522014B (en) * 1997-02-07 2003-03-01 Sepracor Inc Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5939426A (en) 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
US6506767B1 (en) 1997-07-02 2003-01-14 Schering Corporation 8-chloro-6,11-dihydro-11-(4-piperidylidine)-5H-benzo[5,6]cyclohepta[1-2-b] pyridine
EP1032392A4 (en) 1997-10-29 2001-05-09 J Med Pharmaceuticals Inc RHINITIS TREATMENT BY ANTIHISTAMINE / DECONGESTIVUM ADMINISTRATION
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
IL139407A0 (en) 1998-07-10 2001-11-25 Schering Corp 8-CHLORO-6, 11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO [5,6] CYCLOHEPTA [1, 2-b] PYRIDINE ORAL COMPOSITIONS
US6423721B1 (en) * 1998-09-10 2002-07-23 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US6051585A (en) 1998-12-07 2000-04-18 Weinstein; Robert E. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6521254B2 (en) 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6100274A (en) 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
AU2277101A (en) 1999-12-20 2001-07-03 Schering Corporation Stable extended release oral dosage composition
AU2276801A (en) * 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
CN1213752C (zh) * 2000-02-03 2005-08-10 先灵公司 变应性和炎性疾病的治疗
US7405223B2 (en) * 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
EP1289945B1 (en) * 2000-05-19 2004-08-04 Alcon Inc. Aniline disulfide derivatives for treating allergic diseases
US6599913B1 (en) * 2001-06-29 2003-07-29 Schering Corporation Treating allergic and inflammatory conditions

Also Published As

Publication number Publication date
JP2012224642A (ja) 2012-11-15
WO2001045668A2 (en) 2001-06-28
CA2329217C (en) 2006-10-31
KR100936572B1 (ko) 2010-01-13
DK1112738T3 (da) 2010-06-28
ATE463240T1 (de) 2010-04-15
AU7244300A (en) 2001-06-21
CO5251435A1 (es) 2003-02-28
WO2001045668A3 (en) 2001-12-13
AU2009200460B2 (en) 2012-01-19
EP1112738A2 (en) 2001-07-04
JP2001172174A (ja) 2001-06-26
KR20010062542A (ko) 2001-07-07
PL344715A1 (en) 2001-07-02
HUP0004988A2 (hu) 2002-11-28
RU2423106C9 (ru) 2012-06-27
SK287684B6 (sk) 2011-06-06
US20030086971A1 (en) 2003-05-08
US6979463B2 (en) 2005-12-27
HUP0004988A3 (en) 2008-04-28
CZ302860B6 (cs) 2011-12-21
EP1112738A3 (en) 2001-07-18
CN101081224B (zh) 2012-05-30
CN1679569A (zh) 2005-10-12
RU2007104095A (ru) 2008-08-10
BR0006403A (pt) 2001-07-17
ECSP003836A (es) 2002-02-25
SI1112738T1 (sl) 2010-07-30
HU0004988D0 (enExample) 2001-02-28
ES2341751T3 (es) 2010-06-28
EP2196195A2 (en) 2010-06-16
RU2423106C2 (ru) 2011-07-10
SG109438A1 (en) 2005-03-30
CN1301534A (zh) 2001-07-04
EP1112738B1 (en) 2010-04-07
AU2005203771A1 (en) 2005-09-15
PL211573B1 (pl) 2012-05-31
NZ509028A (en) 2002-12-20
US7820199B2 (en) 2010-10-26
NO20006504L (no) 2001-06-21
CY1110693T1 (el) 2015-06-10
HK1034453A1 (en) 2001-10-26
IL140450A (en) 2011-11-30
ZA200007715B (en) 2001-06-20
NO20006504D0 (no) 2000-12-20
SA01210741A (ar) 2005-12-03
SA01210741B1 (ar) 2006-10-31
CN101081224A (zh) 2007-12-05
PT1112738E (pt) 2010-06-04
JP5042403B2 (ja) 2012-10-03
US20060159761A1 (en) 2006-07-20
AR027033A1 (es) 2003-03-12
KR101234940B1 (ko) 2013-02-19
EG23759A (en) 2007-08-08
CA2329217A1 (en) 2001-06-20
CN1211079C (zh) 2005-07-20
PE20010982A1 (es) 2001-09-28
EP2196195A3 (en) 2012-02-29
AU2009200460A1 (en) 2009-02-26
ID28675A (id) 2001-06-21
MXPA00013037A (es) 2003-06-19
NO331645B1 (no) 2012-02-13
KR20110028326A (ko) 2011-03-17
TWI225414B (en) 2004-12-21
RU2303440C2 (ru) 2007-07-27
AU2277101A (en) 2001-07-03
CZ20004812A3 (cs) 2001-08-15
SA06270069B1 (ar) 2009-06-07
SK19672000A3 (sk) 2001-09-11
MY130773A (en) 2007-07-31
AU781924B2 (en) 2005-06-23
DE60044117D1 (de) 2010-05-20
IL140450A0 (en) 2002-02-10
TR200003787A3 (tr) 2001-07-23
JP2008081510A (ja) 2008-04-10

Similar Documents

Publication Publication Date Title
Bauer et al. Assessment of preemptive analgesia with ibuprofen coadministered or not with dexamethasone in third molar surgery: a randomized double-blind controlled clinical trial
BR0006403A (pt) Composição de dosagem oral de liberação prolongada estável
NO951527L (no) Stabilt, oralt doseringspreparat med forlenget frigivelse
ATE374601T1 (de) Multipartikuläre arzneiform, enthaltend mucoadhaesiv formulierte peptid- oder protein- wirkstoffe, sowie ein verfahren zur herstellung der arzneiform
BR0010498A (pt) Composições modernas de medicamentos à base de compostos anticolinergicamente ativos e beta-miméticos
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
AR031822A1 (es) Composiciones farmaceuticas que contienen un inhibidor de cox-ii y un relajante muscular.
BR9814378A (pt) Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase
BR0207883A (pt) Composições de medicamentos à base de anticolenérgicos e inibidores de pde-iv
CY1106845T1 (el) Χρηση της φλουμαζενιλης για την παρασκευη ενος φαρμακου για την αγωγη της εξαρτησεως απο την κοκαϊνη
NO20034709L (no) Fremgangsmåte for fremstilling av lav dose farmasöytisk sammensetning med jevn medikament fordeling og potens
US6521254B2 (en) Single-dose antihistamine/decongestant formulations for treating rhinitis
SG152257A1 (en) Topical preparation containing ambroxol
Spiegel et al. Dysphonia related to medical therapy
EP1501352A4 (en) METHOD AND COMPOSITIONS FOR PROTRACTED ACTIVE SUBSTANCE
HUP0002346A1 (hu) Emlősök elmezavarainak kezelésére szolgáló gyógyszerkészítmény
HUP0004461A2 (hu) Apoliprotein B kiválasztást/mikroszomális trigliceridtranszfer-proteint gátló anyag alkalmazása gyógyászati készítmények előállítására és a fenti gyógyászati készítmények
DK1553943T3 (da) Anvendelse af tenatoprazol til behandling af gastroösofageal refluks
AU2000242484B2 (en) Single-dose antihistamine/decongestant formulations for treating rhinitis
Montes et al. Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study
TR200301552A1 (tr) Rofekoksib' in yeni oral farmakolojik formülasyonları.
Young ULCERS
Ratner et al. Tecastemizole produces rapid and sustained symptom reduction in seasonal allergic rhinitis
UA59359C2 (uk) Фармацевтична композиція та спосіб лікування астми, алергії та запалення у пацієнта
Philip et al. Montelukast in the treatment of nighttime symptoms associated with seasonal allergic rhinitis in double-blind, randomized, placebo-controlled studies